Articles On Medlab Clinical (ASX:MDC)

Listed medical research and development outfit Medlab Clinical was rattling the tin on Thursday morning for $5.4 million in fresh capital. 

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week As markets...

TASALK is a world-leading fully integrated manufacturer and exporter of controlled substance extracts, including medicinal opiates and cannabis products.

Since the start of March, six clinical trials involving cannabis treatments around the world have been halted or cancelled altogether due to COVID19 pandemic but 179 are still recruiting, according to the US registry ClinicalTrials.com. Mor...

North American pot stocks are roaring back from lows in March but the same cannot be said for their antipodean counterparts, many of which continue to wallow. The New Cannabis Ventures Global Cannabis Stock Index soared 26 per cent last wee...

Sales of Epidiolex, the only cannabis drug approved for sale in the US, netted its owner $US116.1m ($180.7m) in sales in the March quarter, proving how lucrative a registered drug can be for marijuana companies. “In the first quarter of 202...

THC Global Group (ASX: THC) will pay $3 million in shares and cash to acquire the Tetra Health network of clinics which provide access to legal medicinal cannabis. Tetra’s network comprises over 630 referring and prescribing physicians, as...

The company has several catalysts signifying progression to watch for. This progression is important as it serves as a stepping-stone to its goal - new approved drugs with strong global potential.

The COVID-19 pandemic has led to 527 clinical trials being shut down in Australia and New Zealand the last two months, up 36 per cent on the prior two months as many organisations deem the patient risk of exposure to be too high. Globally,...

The University of Sydney has validated Medlab’s NanoCelle™ Chloroquine (CQ) nanoparticle characteristics.

An announcement is pending in relation to an extension of Medlab’s NanoCelle™ platform to anti-malaria drugs.

The company is developing therapies for pain management, depression and obesity as well as earning revenue from the sale of nutritional products in Australia and the US.

The medical life science company received a government grant of $75,000 for the clinical depression trial, which was conducted at the Queensland University of Technology.

Zelira Therapeutics (ASX:ZLD) chief Dr Richard Hopkins confirms what your columnist suspected was a self-serving myth perpetuated by overzealous users of the intoxicating herb: no one has ever been recorded as overdosing on cannabis over mi...

Medlab Clinical (ASX:MDC) says it has received the results from an Independent Reviewer for the NanaBis advanced cancer pain trial conducted at the Royal North Shore Hospital with principal investigator Professor Stephen Clarke....

The strong results allow Medlab to focus on phase three designs specifically in the patient group with metastatic bone pain where breast or prostate are the primary cancers.

Results from an advanced cancer pain clinical trial using NanaBis oro-buccal spray developed by Medlab Clinical (ASX: MDC) has found the novel drug candidate to be safe, tolerable and fast-acting with mild adverse effects. The trial at Sydn...

The strong results allow Medlab to focus on phase three designs specifically in the patient group with metastatic bone pain where breast or prostate are the primary cancers.

The S&P/ASX 200 index is on course to start the week on a very disappointing note. In late morning trade the benchmark index is down 5.5% to 5,876.9 points. Four shares that have not let that hold them back today are listed below. Here...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

As a medicinal cannabis company focused on evidence-based science to boost its sales prospects, Medlab Clinical (ASX: MDC) has announced a major milestone today. A clinical trial of Medlab's flagship NanaBis mouth spray at the Royal North...

The NanaBis™ study seeks to recruit 2,000 Australian patients via medical or hospital settings to provide intervention data over a 12-month period.

As market watchers would know, cannabis stocks globally have had a wild ride over the last three years. The volatility is a natural by-product of any frontier market – full of stops and starts as companies try to build out their business mo...

Medlab Clinical (MDC) has formally launched the NanaBis Observation Study in Australia NanaBis is a cannabis-based pain treatment drug and is also being used to investigate cancer pain management The study is looking to find 2000 patients...

The agreement results in manufacturing of the patented cannabis-based medicine being transferred to Tasmanian Alkaloids.

Cann Group (ASX:CAN) is pulling back from its original ambitious Mildura cannabis growing warehouse, saying a global oversupply has led it to change plans. Furthermore, major shareholder Aurora says it won’t participate in any new funding r...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 134-odd small cap health stocks, 51 saw their share prices fall, 73 improved and 15 were flat. The top mover was G Medical (ASX:GMV), which has finally begu...

Only one prescription for medical marijuana has been issued by a doctor in the Northern Territory, according to Minister for Health Natasha Fyles. In a submission to the Senate inquiry into barriers to patient access to marijuana, Fyles sai...

For an industry that’s projected to reach $US20 billion ($29 billion) by 2024 in the US, the cannabidiol (CBD) market there is very much the wild west. A study from researcher Leafreport comparing 3500 products for the sale in the US from 5...

Medlab is a revenue generating research company with an aggressive product development pipeline.

Marijuana is the hottest herb on the planet right now, but while investing in medical cannabis stocks could make you a fortune, it could also risk the house. After a flurry of activity on the ASX in 2017 as the sector kicked off following l...

Medlab Clinical Ltd revealed in December that it had raised $5mln in an oversubscribed share placement

Placement funds will help the company address short-term goals as it prepares for Phase 3 research of the NanaBis™ drug candidate program.

The company’s securities will remain halted until Tuesday, December 17 or when an announcement is released to the market.

Medlab continues the offshore expansion of its nutraceuticals business with a UK partner following its US initiative announced in October.

Insecticide maker Bio-Gene (ASX:BGT) says a trial is proving one of its products is lethal against a particularly difficult to kill mosquito. The Anopheles gambiae mosquito carries malaria and is increasingly resistant to more commonly used...

Listed medicinal cannabis player Medlab Clinical (ASX: MDC) has signed an exclusive distribution agreement with Cultech to break into the UK market. Cultech, a premium manufacturer in the nutritional supplement industry, will distribute t...

New Zealand’s medicines regulator has recommended the country fall in line with Australia’s new codeine restrictions, and pharmaceutical companies are backing the decision. Yesterday, Medsafe recommended that all medications containing code...

Over 100 Australian doctors and 200 patients have been enrolled in the observational study.

Study timelines are progressing as planned and at this point the trial should complete ahead of expectations.

Lately, cannabis stocks in the US have come under pressure, following the rising death toll from vaping that reached 42 so far in 2019, according to media reports. Meanwhile, in Canada, Canopy Growth unveiled that returned cannabis oil prod...

The number of Australian patients being subscribed medicinal cannabis has risen a gigantic 1,191 per cent year-on-year, according to new data. Some 14,357 patients were approved medicinal cannabis, compared with 1,112 this time last year, a...

By AEST 3:20 PM, S&P/ASX 200 index was up by 35.7 points at 6,759.8. The below-mentioned stocks were among the top gainers on ASX today (i.e., 11 November 2019). Let’s take a closer look at these stocks and their recent updates. Highli...

More than 840 bottles were dispensed in October and a final patient was recruited to a study at Royal North Shore Hospital.

It certainly has been a busy day for the local cannabis industry. A large number of announcements have been made by Australian pot stocks today. Here’s a summary of what’s happening: The BOD Australia Ltd (ASX: BDA) share price is up over...

The company’s assets include medical cannabis pharmaceutical solutions to help people manage pain.

Cannabis Shares Valuing a cannabis company is becoming an increasingly difficult task. Lately, the cannabis shares have been taking a beat in the domestic markets, falling from their respective all-time highs. The table below provides you w...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

In order to boost their returns, investors usually tend to search for stocks of the companies that are likely to report relatively higher revenues and earnings in the future. The stocks that are expected to grow substantially above the aver...